Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities - PubMed
2 days ago
- #Metabolic reprogramming
- #Cancer therapy
- #Hepatocellular carcinoma
- Metabolic reprogramming is a hallmark of cancer, including hepatocellular carcinoma (HCC).
- Cancer cells exhibit enhanced glucose and glutamine uptake, increased glycolysis, pentose phosphate pathway activity, de novo lipogenesis, and altered amino acid metabolism.
- Key signaling regulators involved in cancer metabolic reprogramming include mTORC1, c-Myc, HIF-1α, ATF4, NRF2, and SREBP1.
- The review highlights interconnections among metabolic pathways and signaling hubs that orchestrate metabolic crosstalk.
- Metabolic targets and metabolism-directed therapeutic agents with developmental potential are summarized, including TVB-2640 and CB-839 in clinical trials.
- Challenges include adverse effects on normal tissues and drug resistance driven by metabolic plasticity.
- Innovative strategies include combination therapy, overcoming resistance, early cancer detection, immunometabolism, and metabolomics.